Is Zimmer Biomet (ZBH) Attractive After Mixed Returns And A Bullish DCF Estimate

Simply Wall St.01-07

If you have been wondering whether Zimmer Biomet Holdings is offering good value at around US$94.75, this article walks through what the current price might be telling you. The stock has recently seen...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601388667?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-01-07 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601388667","market":"nz","top_or_hot":-1,"title":"Is Zimmer Biomet (ZBH) Attractive After Mixed Returns And A Bullish DCF Estimate","media":"Simply Wall St.","content":"<div>\n<p>If you have been wondering whether Zimmer Biomet Holdings is offering good value at around US$94.75, this article walks through what the current price might be telling you. The stock has recently seen...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/is-zimmer-biomet-zbh-attractive-after-mixed-returns-and-a-bu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Zimmer Biomet (ZBH) Attractive After Mixed Returns And A Bullish DCF Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Zimmer Biomet (ZBH) Attractive After Mixed Returns And A Bullish DCF Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-07 22:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/is-zimmer-biomet-zbh-attractive-after-mixed-returns-and-a-bu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you have been wondering whether Zimmer Biomet Holdings is offering good value at around US$94.75, this article walks through what the current price might be telling you. The stock has recently seen...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/is-zimmer-biomet-zbh-attractive-after-mixed-returns-and-a-bu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/is-zimmer-biomet-zbh-attractive-after-mixed-returns-and-a-bu","article_id":"2601388667","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/is-zimmer-biomet-zbh-attractive-after-mixed-returns-and-a-bu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601388667","pubTimestamp":1767796299,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you have been wondering whether Zimmer Biomet Holdings is offering good value at around US$94.75, this article walks through what the current price might be telling you.\nThe stock has recently seen mixed performance, with a 4.4% gain over the last 7 days, a 0.5% return over 30 days, a 5.3% return year to date, but a 7.2% decline over the last year and deeper falls of 22.5% and 36.3% across the past 3 and 5 years.\nThese moves sit against a backdrop of ongoing interest in orthopedic and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4504":"桥水持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","BK4588":"碎股","BK4112":"金融交易所和数据","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4585":"ETF&股票定投概念","ZBH":"齐默巴奥米特控股","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4566":"资本集团","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC"},"translate_title":"在混合回报和看涨的DCF估计之后，Zimmer Biomet(ZBH)是否有吸引力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":1.98},"content_text":"If you have been wondering whether Zimmer Biomet Holdings is offering good value at around US$94.75, this article walks through what the current price might be telling you. The stock has recently seen mixed performance, with a 4.4% gain over the last 7 days, a 0.5% return over 30 days, a 5.3% return year to date, but a 7.2% decline over the last year and deeper falls of 22.5% and 36.3% across the past 3 and 5 years. These moves sit against a backdrop of ongoing interest in orthopedic and medical device companies. In this space, investors frequently weigh long product cycles, regulatory developments, and procedure volumes when reassessing risk and opportunity. For Zimmer Biomet, that broader sector context helps frame whether recent price action is simply noise or part of a longer shift in how the market views the company. On our checks, Zimmer Biomet scores 5 out of 6 on undervaluation tests, giving it a valuation score of 5. Next we will look at how different valuation approaches line up, before finishing with a perspective that can help you make more sense of these numbers.  Find out why Zimmer Biomet Holdings's -7.2% return over the last year is lagging behind its peers. AdvertisementApproach 1: Zimmer Biomet Holdings Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those back to a single present value figure. For Zimmer Biomet Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach. The company’s latest twelve month free cash flow is about $1.04b. Analysts provide explicit free cash flow estimates for the next few years, and beyond that, Simply Wall St extends the projections. For example, projected free cash flow for 2028 is $1.996b, and the model includes a full set of yearly projections out to 2035, each discounted back to reflect today’s dollars. Bringing all those discounted cash flows together gives an estimated intrinsic value of about $167.07 per share. Against a current share price of roughly $94.75, the DCF output suggests the stock is around 43.3% undervalued based on these assumptions. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Zimmer Biomet Holdings is undervalued by 43.3%. Track this in your watchlist or portfolio, or discover 877 more undervalued stocks based on cash flows. ZBH Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Zimmer Biomet Holdings. Approach 2: Zimmer Biomet Holdings Price vs Earnings For a profitable company like Zimmer Biomet Holdings, the P/E ratio is a useful starting point because it tells you how much you are paying for each dollar of current earnings. What counts as a normal or fair P/E often reflects how the market views a company’s growth prospects and risk profile, with higher growth or lower perceived risk usually associated with a higher multiple. Zimmer Biomet currently trades on a P/E of 23.3x. That sits below the Medical Equipment industry average of 30.7x and also below the broader peer group average of 47.1x. Simply Wall St calculates a Fair Ratio of 29.1x for Zimmer Biomet, which is the P/E level that would be expected after factoring in its earnings growth profile, industry, profit margins, market cap and company specific risks. This Fair Ratio can be more informative than a straight comparison with peers or the industry because it adjusts for key company characteristics rather than assuming all businesses deserve the same multiple. Comparing Zimmer Biomet’s current 23.3x P/E with the 29.1x Fair Ratio indicates the shares are trading below the level implied by those fundamentals. Result: UNDERVALUED NYSE:ZBH P/E Ratio as at Jan 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1448 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Zimmer Biomet Holdings Narrative Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St you can use Narratives, which let you set out your own story for Zimmer Biomet Holdings, link that story to explicit forecasts for revenue, earnings and margins, translate those into a fair value, then compare that fair value with the current price to help you decide what to do. The narrative updates as new news or earnings arrive, so one investor might frame Zimmer Biomet around higher growth, margin expansion and a fair value closer to US$138, while another might focus more on pricing pressure, regulatory and execution risks and settle on a fair value closer to US$96. Do you think there's more to the story for Zimmer Biomet Holdings? Head over to our Community to see what others are saying! NYSE:ZBH 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zimmer Biomet Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601388667","isCrawlerRequest":true}